Overview
To evaluate the real-world effectiveness and implementation strategies for mPATH-Lung, investigators propose a pragmatic, randomized controlled trial across an academic Learning Health System. The trial will contrast several approaches to participant outreach and will specifically target engaging fully powered cohorts of racial/ethnic minorities and rural residents.
Description
Primary Objective: Evaluate the real-world effectiveness of mPATH-Lung in increasing lung cancer screening rates across diverse populations.
Secondary Objectives
- Compare the differential effectiveness of three outreach strategies for engaging participants with mPATH-Lung across vulnerable rural or ethnic/racial minority population subgroups.
- Estimate the additional revenue generated by mPATH-Lung through increased screening and downstream care.
- Evaluate the potential for over-screening and the impact of applying HEDIS-based exclusion criteria
Eligibility
Inclusion Criteria:
- Adult patient (≥ 18 years old)
- Patient operated on at Strasbourg University Hospital between January 1, 2023, and December 31, 2023, for total knee, shoulder, or hip replacement.
- Patients who underwent surgery at Strasbourg University Hospital between March 1, 2025, and July 31, 2025, involving surgery requiring intraoperative antibiotic prophylaxis.
Exclusion Criteria:
- Patients with a surgical indication without the use of implants.
- Patients with a surgical indication without antibiotic prophylaxis.
